13F-HR filed by Octagon Capital Advisors LP
Octagon Capital Advisors LP filed this 13F-HR for the quarter ended 2022-03-31, filed 2022-05-16, with 24 holding rows worth $462,555,000.
- Accession
- 0001214659-22-007019
- Filer
- CIK 1839435
- Filed
- 2022-05-16
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q1 2022
A holdings report, 24 entries on the cover page, a total value of $462,555,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $462,555,000 with VALUE read as thousands by filing date, 13F file number 028-20958. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| APELLIS PHARMACEUTICALS INC | 03753U106 | COM | 2,340,059 | $118,898,000 | thousands by filing date | |
| ARCUS BIOSCIENCES INC | 03969F109 | COM | 2,489,974 | $78,584,000 | thousands by filing date | |
| CELLDEX THERAPEUTICS INC NEW | 15117B202 | COM NEW | 761,398 | $25,933,000 | thousands by filing date | |
| 4D MOLECULAR THERAPEUTICS INC COM | 35104E100 | Stock | 1,566,895 | $23,691,000 | thousands by filing date | |
| BRIDGEBIO PHARMA INC | 10806X102 | COM | 2,267,486 | $23,015,000 | thousands by filing date | |
| GOSSAMER BIO INC COM | 38341P102 | Stock | 2,563,138 | $22,248,000 | thousands by filing date | |
| CHINOOK THERAPEUTICS INC | 16961L106 | COM | 1,356,250 | $22,188,000 | thousands by filing date | |
| KEROS THERAPEUTICS INC COM | 492327101 | Stock | 340,214 | $18,501,000 | thousands by filing date | |
| STOKE THERAPEUTICS INC | 86150R107 | COM | 813,456 | $17,123,000 | thousands by filing date | |
| NOVABRIDGE BIOSCIENCES | 44975P103 | CMN | 1,049,691 | $17,047,000 | thousands by filing date | |
| ITEOS THERAPEUTICS INC | 46565G104 | COM | 450,776 | $14,506,000 | thousands by filing date | |
| VERA THERAPEUTICS INC | 92337R101 | COMMON STOCK | 575,000 | $13,507,000 | thousands by filing date | |
| ARVINAS INC | 04335A105 | COM | 178,500 | $12,013,000 | thousands by filing date | |
| HORIZON THERAPEUTICS PLC | G46188101 | SHS | 100,000 | $10,521,000 | thousands by filing date | |
| CENTURY THERAPEUTICS INC | 15673T100 | COM | 658,266 | $8,288,000 | thousands by filing date | |
| IMMUNOVANT INC | 45258J102 | COM | 1,475,000 | $8,127,000 | thousands by filing date | |
| SURFACE ONCOLOGY INC | 86877M209 | COM | 2,300,000 | $6,762,000 | thousands by filing date | |
| AVIDITY BIOSCIENCES INC COM | 05370A108 | Stock | 321,641 | $5,941,000 | thousands by filing date | |
| DYNE THERAPEUTICS INC COM | 26818M108 | Stock | 525,284 | $5,064,000 | thousands by filing date | |
| SPDR SER TR | 78464A870 | S&P BIOTECH | 55,800 | $5,015,000 | thousands by filing date | |
| PROMETHEUS BIOSCIENCES INC | 74349U108 | COM | 80,000 | $3,021,000 | thousands by filing date | |
| OMEGA THERAPEUTICS INC | 68217N105 | COMMON STOCK | 176,470 | $1,101,000 | thousands by filing date | |
| CONNECT BIOPHARMA HLDGS LTD | 207523101 | SHS | 279,921 | $845,000 | thousands by filing date | |
| AMBRX BIOPHARMA, INC. SPONSORED ADR | 02290A102 | COM | 149,400 | $616,000 | thousands by filing date |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001214659-22-007019 | this filing | 2022-05-16 | acceptance time not in the bulk data set |